Sugi Predict

Sugi Predict / Compounds / SCHEMBL212773

SCHEMBL212773

SCHEMBL212773

C=CCC(NC(=O)OC(C)(C)C)C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ CTSK P43235 8/20 0.47
▸ CTSS P25774 6/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ PPARA Q07869 6/20 0.45
▸ PPARG P37231 5/20 0.45
▸ CTSL P07711 1/20 0.44
▸ CTSB P07858 1/20 0.44
▸ ACE P12821 1/20 0.44
▸ PPARD Q03181 2/20 0.43
▸ CA1 P00915 1/20 0.42
▸ CA2 P00918 1/20 0.42
▸ CA7 P43166 1/20 0.42
▸ MAPT P10636 1/20 0.42
▸ IDO1 P14902 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL212772 1.00 CTSK (0.47) CTSKCTSSSMN1; SMN2PPARAPPARG
SCHEMBL2728681 1.00 CTSK (0.47) CTSKCTSSSMN1; SMN2PPARAPPARG
SCHEMBL21904767 0.87 CTSK (0.44) CTSKCTSSSMN1; SMN2CTSLCTSB
SCHEMBL15083313 0.87 SMN1; SMN2 (0.49) CTSKCTSSSMN1; SMN2CTSLCTSB
SCHEMBL4038634 0.87 SMN1; SMN2 (0.46) CTSKCTSSSMN1; SMN2CTSLCTSB
SCHEMBL16289367 0.87 SMN1; SMN2 (0.49) CTSKCTSSSMN1; SMN2CTSLCTSB
SCHEMBL4038638 0.87 SMN1; SMN2 (0.46) CTSKCTSSSMN1; SMN2CTSLCTSB
SCHEMBL2179710 0.86 GRIK1 (0.44) CTSKCTSSSMN1; SMN2PPARAPPARG
SCHEMBL29273137 0.86 GRIK1 (0.44) CTSKCTSSSMN1; SMN2PPARAPPARG
SCHEMBL13571099 0.86 GRIK1 (0.44) CTSKCTSSSMN1; SMN2PPARAPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 356 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111187212-B Washing-free type photoaffinity linker, preparation method and application thereof 西安交通大学 2021-04-20 — — CN claimed
CN-111187212-A Washing-free type photoaffinity linker, preparation method and application thereof 西安交通大学 2020-05-22 — — CN claimed
EP-3829559-B1 INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION MERCK SHARP & DOHME LLC (US) 2026-05-13 — — EP disclosed
EP-4712969-A1 CYCLIN INHIBITORS Circle Pharma, Inc. (US) 2026-03-25 — — EP disclosed
US-20260015373-A1 STAT6 MODULATORS AND USES THEREOF RECLUDIX PHARMA INC (US) 2026-01-15 — — US disclosed
EP-3604326-B1 PEPTIDE COMPOUND AND METHOD FOR PRODUCING SAME, COMPOSITION FOR SCREENING USE, AND METHOD FOR SELECTING PEPTIDE COMPOUND FUJIFILM CORP (JP) 2026-01-07 — — EP disclosed
US-12473331-B2 Macrocyclic compounds as proteasome inhibitors CORNELL UNIVERSITY (US) 2025-11-18 — — US disclosed
US-12415835-B2 Peptide-compound cyclization method CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-09-16 — — US disclosed
US-12404274-B2 Macrocycles as factor xia inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2025-09-02 — — US disclosed
US-20250215030-A1 STAT MODULATORS AND USES THEREOF RECLUDIX PHARMA, INC. 2025-07-03 — — US disclosed
US-20250215029-A1 STAT MODULATORS AND USES THEREOF RECLUDIX PHARMA, INC. 2025-07-03 — — US disclosed
US-20020156018-A1 Treatment of parasitic diseases by inhibition of cysteine proteases of the papain superfamily THOMPSON SCOTT KEVIN (US) 2002-10-24 — — US disclosed
US-6423869-B1 BACTERICIDES, ANTIULCER AGENTS TAKEDA CHEMICAL INDUSTRIES, INC. (JP) 2002-07-23 — — US disclosed
EP-0934064-A4 THROMBIN INHIBITORS MERCK & CO INC (US) 2002-01-09 — — EP disclosed
EP-1149843-A1 SUBSTITUTED PHENETHYLAMINE DERIVATIVES CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2001-10-31 — — EP disclosed
CN-1304447-A Treatment of parasitic diseases by inhibition of cysteine proteases of papain superfamily SMITHKLINE BEECHAM CORP (US) 2001-07-18 — — CN disclosed
EP-0934064-A1 THROMBIN INHIBITORS Merck & Co., Inc. (US) 1999-08-11 — — EP disclosed
US-5869487-A HIGH SELECTIVITY FOR THROMBIN; TREATING UNSTABLE ANGINA, MYOCARDIAL INFARCTION, ATRIAL FIBRILLATION, DEEP VEIN THROMBOSIS AND OTHER DISEASES MERCK & CO., INC. (US) 1999-02-09 — — US disclosed
WO-1998017274-A1 THROMBIN INHIBITORS MERCK & CO., INC. (US) 1998-04-30 — — WO disclosed
US-5508466-A REACTING MIXTURE OF N-PROTECTED-ALPHA-SUBSTITUTED-GLYCINE CATION DERIVATIVE AND ELEMENTAL ZINC WITH ORGANIC HALIDE IN POLAR SOLVENT G.D. SEARLE & CO. (US) 1996-04-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12404274-B2 Macrocycles as factor xia inhibitors TFPI, TFPI2, F11 CTSK 85/4885CTSS 213/4885SMN1; SMN2 3689/4885
US-20250215030-A1 STAT MODULATORS AND USES THEREOF STAT6, STAT3, STAT5A CTSK 2968/4885CTSS 3548/4885SMN1; SMN2 3676/4885
US-20260015373-A1 STAT6 MODULATORS AND USES THEREOF STAT6, STAT5A, STAT3 CTSK 2775/4885CTSS 3327/4885SMN1; SMN2 4276/4885
US-20250215029-A1 STAT MODULATORS AND USES THEREOF STAT6, STAT3, STAT5A CTSK 3186/4885CTSS 3834/4885SMN1; SMN2 3779/4885
US-12473331-B2 Macrocyclic compounds as proteasome inhibitors PSMB5, PSMB1, PSMB3 CTSK 1101/4885CTSS 640/4885SMN1; SMN2 271/4885
US-20020156018-A1 Treatment of parasitic diseases by inhibition of cysteine proteases of the papain superfamily PEPD, PREP, CPN1 CTSK 64/4885CTSS 4/4885SMN1; SMN2 4763/4885
US-12415835-B2 Peptide-compound cyclization method VIP, NGLY1, GLP1R CTSK 188/4885CTSS 273/4885SMN1; SMN2 4620/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.